Immunic Stock

Immunic EBIT

The EBIT of Immunic (IMUX) as of Aug 4, 2026 is -103.23 M USD. In the previous year, EBIT was -98.05 M USD — a change of 5.28% (lower).

EBIT

-103.23 MUSD

YoY

5.28%

Last updated:

In 2026, Immunic's EBIT was -103.23 M USD, a 5.28% increase from the -98.05 M USD EBIT recorded in the previous year.

The Immunic EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2024
-98.05 base
Jan 1, 2025
-103.23 base
Jan 1, 2026 (e)
-114.25 base
Jan 1, 2027 (e)
-119.33 base
Jan 1, 2028 (e)
-14.52 base
Jan 1, 2029 (e)
96.23 base
Jan 1, 2030 (e)
421.01 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (M USD)
2031 est -
2030 est 421.01
2029 est 96.23
2028 est -14.52
2027 est -119.33
2026 est -114.25
2025 -103.23
2024 -98.05
2023 -99.22
2022 -119.49
2021 -91.67
2020 -48.97
2019 -37.03
2018 -42.02
2017 -52.66
2016 -41.27
2015 -52.12
2014 -50.34
2013 -31.40
2012 -9.58
2011 -8.58
Access this data via the Eulerpool API

Immunic Revenue

Immunic Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
0.00 USD
-98.05 M USD
-100.51 M USD
Jan 1, 2025
0.00 USD
-103.23 M USD
-97.17 M USD
Jan 1, 2026 (e)
12.50 M USD
-114.25 M USD
-529.90 M USD
Jan 1, 2027 (e)
12.50 M USD
-119.33 M USD
-428.05 M USD
Jan 1, 2028 (e)
74.86 M USD
-14.52 M USD
-375.07 M USD
Jan 1, 2029 (e)
231.54 M USD
96.23 M USD
-77.22 M USD
Jan 1, 2030 (e)
416.87 M USD
421.01 M USD
263.89 M USD
Jan 1, 2031 (e)
1.58 B USD
0.00 USD
179.73 M USD

Immunic Margins

Immunic stock margins

The Immunic margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immunic. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immunic.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
96.57 %
- %
- %
Jan 1, 2025
96.57 %
- %
- %
Jan 1, 2026 (e)
96.57 %
-913.99 %
-4,239.21 %
Jan 1, 2027 (e)
96.57 %
-954.61 %
-3,424.37 %
Jan 1, 2028 (e)
96.57 %
-19.40 %
-501.06 %
Jan 1, 2029 (e)
96.57 %
41.56 %
-33.35 %
Jan 1, 2030 (e)
96.57 %
100.99 %
63.30 %
Jan 1, 2031 (e)
96.57 %
0.00 %
11.37 %

Immunic Stock analysis

What does Immunic do? Immunic Inc is a biotechnology company specialized in the development of therapeutics for chronic inflammatory and autoimmune diseases. The company was founded in 2016 as a spin-off of the Max Planck Institute for Infection Biology in Berlin and is based in New York City. Immunic Inc aims to develop innovative drugs that improve the quality of life for patients with chronic inflammatory and autoimmune diseases and positively influence the course of their conditions. The business activities of Immunic Inc include the identification of new active substances, drug development, clinical studies, and drug approval by regulatory authorities. To accelerate drug development, the company collaborates with academic, regulatory, and pharmaceutical partners. Immunic Inc offers products in three different areas: autoimmune diseases, inflammatory diseases, and infectious diseases. Each area has various products and pipelines currently in development. In the field of autoimmune diseases, the main product of Immunic Inc is the substance IMU-838. This drug is a highly effective inhibitor of the DHODH enzyme family, which plays an essential role in mitochondrial DNA synthesis. IMU-838 is a very selective DHODH inhibitor with disease-specific effects against various autoimmune diseases. IMU-838 is one of the most promising candidates of Immunic Inc and is currently in phase II studies for the treatment of multiple sclerosis (MS), ulcerative colitis, and chronic inflammatory bowel diseases (CED). In the field of inflammatory diseases, Immunic Inc is developing a drug based on IMM-124E. This medication is an orally administered therapeutic agent that inhibits inflammatory reactions in the gastrointestinal tract. IMM-124E was initially developed as an antidote for arsenic poisoning but also shows promising results in the treatment of inflammatory diseases such as nonalcoholic steatohepatitis (NASH) and liver fibrosis. IMM-124E is currently in phase II studies for the treatment of these conditions. In the field of infectious diseases, Immunic Inc is developing various drugs that are effective against infections. This includes IMU-935, a selective HSV-1 inhibitor that has shown promise in the treatment of herpes simplex viruses (HSV) and other viral infections. IMU-935 also exhibits good activity against influenza viruses and cytomegaloviruses and is currently in phase I studies. Immunic Inc is an innovative biotechnology company developing innovative therapeutics for chronic inflammatory and autoimmune diseases. The company aims to improve the lives of patients with chronic conditions and positively influence the course of their diseases. By focusing on three different areas, the company is developing a broad portfolio of drugs in various stages of development and clinical testing. Immunic Inc has established strong partnerships with academic, regulatory, and pharmaceutical partners and will continue to operate successfully in the biotechnology field with promising products and pipelines in the coming years. Immunic is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Immunic's EBIT

Immunic's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Immunic's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Immunic's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Immunic’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Immunic stock

EBIT of Immunic is -103.23 M USD in 2026.

EBIT of Immunic changed from -98.05 M USD to -103.23 M USD, representing a 5.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Immunic since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Immunic historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Immunic

All Key Metrics — Immunic